Bioidentical vs. Synthetic Hormones: What the Evidence Actually Shows

In November 2023, the American College of Obstetricians and Gynecologists published a clinical consensus statement that directly addresses one of the most contentious areas in menopause care: the claims surrounding compounded bioidentical hormone therapy. The term "bioidentical" refers to hormones that are chemically identical to those produced by the human body — primarily estradiol and progesterone. These molecules exist in both FDA-approved formulations and custom-compounded preparations. The distinction matters because compounding pharmacies frequently market their products as "natural" and inherently safer than FDA-approved alternatives, despite the absence of randomized controlled trial evidence to support those claims.

ACOG's statement is measured but clear: the claims that compounded bioidentical therapy lowers the risk of breast cancer, coronary artery disease, stroke, or thromboembolism are not supported by scientific research. Compounded products are not subject to the same regulatory oversight as FDA-approved medications — they are not required to demonstrate safety, efficacy, or consistency in dosing. The statement acknowledges that some FDA-approved bioidentical formulations (such as transdermal estradiol and oral micronized progesterone) do have evidence supporting certain advantages over older synthetic progestins, but it draws a firm line between these regulated products and the unregulated compounding market.

Why This Matters

The bioidentical hormone debate is fueled in part by an information vacuum. Women experiencing significant menopause symptoms are understandably drawn to treatments marketed as safer and more natural, especially when they have been told for two decades that hormone therapy is dangerous. The problem is not the molecules — it is the gap between evidence and marketing. For women navigating this landscape, having clear, tracked data on their symptoms, hormone levels, and treatment responses is the best defense against both under-treatment and over-promising. A platform that logs symptom severity alongside treatment changes allows women and their providers to see what is actually working, regardless of what the label says.